BSE filing, NSE: DRAGARWQ. Summary written from the filing by ALFA Finder's alert engine.
Dr. Agarwal's Eye Hospital Ltd: key numbers
- Share price
- ₹5,100.00
- Market cap
- ₹2,397 Cr
- Revenue (annual)
- ₹470.9 Cr
- Net profit (annual)
- ₹70.10 Cr
- P/E (TTM)
- 31.4×Sector 51.1×
- Promoter holding
- 72.67%+0.00% QoQ
- FII holding
- 2.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwal's Eye Hospital Ltd
All →Dr. Agarwal's Eye Hospital Acquisition Worth ₹711.2 Cr
Dr. Agarwal's Eye Hospital Limited has completed its amalgamation with Dr. Agarwal's Health Care Limited, with the transaction valued at ₹711.21 Crore.
- Value
- ₹711.2 Cr
Dr. Agarwal's Eye Hospital Acquisition
Dr. Agarwal's Eye Hospital announced the effectiveness of its Scheme of Amalgamation starting November 01, 2026, and fixed a record date for share allotment.
Dr. Agarwal's Eye Hospital Acquisition
The NCLT Chennai Bench has sanctioned the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited. The company awaits the order copy.
Dr. Agarwal's Eye Hospital Annual General Meeting
Dr. Agarwal's Eye Hospital Limited held its 32nd Annual General Meeting on September 09, 2026. The meeting concluded with the approval of six business resolutions.
Dr. Agarwal's Eye Hospital Business Update
Dr. Agarwals Eye Hospital inaugurated its new Pinhole Pupilloplasty Centre in Chennai. This facility provides advanced specialized clinical treatments for patients with complex corneal conditions.
Dr. Agarwal's Eye Hospital Annual General Meeting
Dr. Agarwal’s Eye Hospital will hold its 32nd Annual General Meeting on September 09, 2026. The meeting includes approval for a final dividend of ₹4.00 per share.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.